Rahway, New Jersey Thursday, September 26, 2024, 09:00 Hrs [IST] ...

Japan’s MHLF approves Padcev with Keytruda for first-line treatment of radically unresectable urothelial carcinoma: Tokyo Wednesday, September 25, 2024, 11:00 Hrs [IST] Astellas ...

Enfortumab vedotin plus pembrolizumab was previously granted a priority review designation from the MHLW. Japan’s Ministry of Health, Labour, and Welfare (MHLW) has approved the combination of ...

Non-muscle-invasive bladder cancer (NMIBC) is a type of bladder cancer where the tumor remains confined to the bladder's ...

Painful urination is common in the early stages of bladder cancer, but more advanced or radiating pain will not usually develop until later stages. Feeling tired and weak is a common symptom of most ...

Rosenberg, MD, to discuss recent data from a phase 2 study investigating enfortumab vedotin plus pembrolizumab for the treatment of patients with locally advanced or metastatic bladder cancer. Expert ...

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients with locally advanced or metastatic bladder cancer.

To our knowledge, to date, no study has used an algorithm to categorize patients with bladder cancer (BC) by disease stage (non–muscle-invasive BC ... 78.4 0.4169 2 Code lists for systemic therapies ...

The phase 3 trial will assess the anti-tumor activity of 9MW2821 plus toripalimab vs chemotherapy in patients with locally advanced or metastatic urothelial carcinoma.

Follow-up with cholesterol control and audiological assessments is suggested for cisplatin-treated patients with cancer. Srigowri Kota, MSN, BA, APRN, AGNP-C, AOCNP, provides an in-depth look at ...

The addition of pembrolizumab to Pfizer’s antibody-drug conjugate Padcev (enfortumab vedotin-ejfv) for untreated, advanced/metastatic bladder cancer was a highlight of last year’s ESMO ...